-
BP8 Sources Bird’s Nest Products from Chinese State-Owned Conglomerate China National Pharmaceutical Group Corporation (Commonly Known as Sinopharm)
06 Jun 2024 04:43 GMT
… .S. Food and Drug Administration (FDA) on May 28, …
BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive … helped to establish the biotechnology industry and remains on … existing portfolio of medicines to treat cancer, heart disease, …
-
UCART22 Earns Orphan Drug Designation for Acute Lymphoblastic Leukemia in Europe
05 Jun 2024 18:17 GMT
… phase 1 BALLI-01 trial (NCT04150497) in patients … , MD, PhD, chief medical officer of Cellectis Biologics, … who received prior treatment with multiagent chemotherapy, blinatumomab (Blincyto), … References
Cellectis receives orphan drug designation for UCART22, …
-
Biological Therapies for Cancer
31 May 2024 18:11 GMT
… of B-cell non-Hodgkin lymphoma who have not … T-cell receptor. Blinatumomab brings leukemia cells … antigen).
The first FDA-approved cancer treatment vaccine, sipuleucel-T (Provenge … Single versus combination immunotherapy drug treatment in melanoma. Expert …
-
IMDELLTRA (tarlatamab) for the Treatment of Extensive-Stage Small Cell Lung Cancer, USA
25 May 2024 03:46 GMT
… the treatment of extensive-stage small cell lung cancer (ES … Developed by Amgen, a biotechnology company based in the US … s second FDA-approved BiTE molecule following BLINCYTO® (blinatumomab), a … trials on IMDELLTRA
The Phase II DeLLphi-301 clinical trial …
-
Amgen adds BiTE to its cancer range as FDA clears Imdelltra
17 May 2024 10:21 GMT
… drugs with the FDA approval of tarlatamab for advanced small cell lung cancer … Amgen’s Blincyto (blinatumomab) BiTE for acute lymphoblastic … moment” for SCLC treatment offering “a transformative option … #47;2 trial in neuroendocrine prostate cancer (NEPC) and …
-
EHA 2024 Results From Five Studies Of Ascentage Pharma's Key Drug Candidates Selected For Presentations At 2024 European Hematology Association Hybrid Congress
16 May 2024 02:59 GMT
… ;s core drug candidate developed for the treatment of drug-resistant chronic myeloid … biotechnology and pharmaceutical companies and research institutes such as UNITY Biotechnology, MD Anderson Cancer …
-
Novartis’ leukaemia treatment to be made available on the NHS
02 May 2024 12:40 GMT
… within the NHS’s Cancer Drugs Fund (CDF) since … survival was 72% following treatment. Clinical trial evidence for tisagenlecleucel … 7.5 months for blinatumomab and a median overall … other standard treatments.
Helen Knight, director of medicines evaluation at …
-
'A Perfect Match': Little Girl Survives Cancer After 2-Year-Old Sister Donates Bone Marrow
03 May 2024 12:26 GMT
… , she received a relatively new drug called blinatumomab, which got her leukemia … with cancer, offering significantly less pain and despair than traditional chemotherapy treatments … proved successful, Ruby's medical team began searching for donors …
-
Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research
30 Apr 2024 12:00 GMT
… -in-class thrombopoietin), blinatumomab (first-in-class … drug. In addition, he has worked at various biotech and pharmaceutical … oncology, ADC and a vaccine approach. Dr. Cha … cancer treatment. By combining its novel oncology pipeline with proven cancer …
-
After Childhood Cancer Diagnosis, Donor Bone Marrow from Little Sister Sends it into Remission
30 Apr 2024 17:15 GMT
… received a relatively new drug called blinatumomab, which got her … her bone marrow transplant.”
Blinatumomab, or “blina” as … cancers with significantly less pain and despair than heavier chemo treatments … successful, Ruby’s medical staff began to look …